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Background: Lipoprotein-associated phospholipase A2 (LpPLA2), a recognized specific marker of vascular inflammation, is an independent 
predictor of cardiovascular risk. However, it is unknown whether the predictive ability of Lp-PLA2 differs among those with varying number of risk 
factors for coronary artery disease (CAD) diagnosis.
Methods: LpPLA2 (PLACTM test, diaDexus, Inc.) was measured from samples donated by consenting patients (N=1,487) enrolled in the 
angiographic registry of the Intermountain Heart Collaborative Study. Patients were stratified by the number of risk factors present at angiography 
(<1, 2, 3, and >4). Risk factors included age (<70 or >70), sex, hyperlipidemia, hypertension, smoking, diabetes, and family history of CAD. LpPLA2 
was stratified at its median (346.6 ng/mL). Multivariable logistic regression was utilized to determine associations between CAD (stenosis >70%) 
and LpPLA2 among patients with varying numbers of risk factors.
Results: Average age was 63±12 years, 70% were male and 76% had CAD. The number of patients in each risk factor category was: <1: 261, 2: 
349, 3: 406, and >4: 471. LpPLA2 was significantly associated with CAD diagnosis (HR=1.69, p=0.001). A trend towards an increase in CAD risk 
was found with increasing numbers of risk factors [(vs. <1): 2: HR=1.34, p=0.27; 3: HR=1.23, p=0.56; >4: HR=1.35, p=0.52]. As the number of 
risk factors increased, the association between LpPLA2 became less predictive of CAD (risk factors <1: OR=2.87, p=0.004; 2: OR=1.71, p=0.08; 3: 
OR=1.94, p=0.03; >4: OR=1.16, p=0.63).
Conclusions: LpPLA2 is most strongly associated with CAD risk among patients with few or no traditional cardiovascular risk factors. This finding 
emphasizes the independence of LpPLA2 as cardiovascular risk factor and suggests that its utility as a screening tool is greatest among patients 
who are otherwise at low risk for CAD.
